Safety and continuity of second and thirdline therapy with paclitaxel or irinotecan for advanced and recurrent gastric cancer

Author：                

Publisher： Spandidos Publications

ISSN： 2049-9469

Source： Molecular and Clinical Oncology, Vol.2, Iss.3, 2014-01, pp. : 466-472

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Phase II study on the combination of irinotecan plus cisplatin as a secondline therapy in patients with advanced or recurrent gastric cancer

By                    

Molecular and Clinical Oncology, Vol. 1, Iss. 4, 2013-01 ,pp. : 749-752

Spandidos Publications

Access to resources Recommend Favorite

Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?

By Durães Cecília   Almeida Gabriela   Seruca Raquel   Oliveira Carla   Carneiro Fátima  

Virchows Archiv, Vol. 464, Iss. 3, 2014-03 ,pp. : 367-378

Springer Publishing Company

Access to resources Recommend Favorite

Application of Mesenchymal Stem Cells in the Targeted Gene Therapy for Gastric Cancer

By  

Current Stem Cell Research & Therapy, Vol. 11, Iss. 5, 2016-07 ,pp. : 434-439

Bentham Science Publishers

Access to resources Recommend Favorite

Application of Mesenchymal Stem Cells in the Targeted Gene Therapy for Gastric Cancer

By  

Current Stem Cell Research & Therapy, Vol. 11, Iss. 5, 2016-05 ,pp. : 434-439

Bentham Science Publishers

Access to resources Recommend Favorite

Expression of human epidermal growth factor receptor 2 in primary and paired parenchymal recurrent and/or metastatic sites of gastric cancer

By                

Molecular and Clinical Oncology, Vol. 2, Iss. 5, 2014-01 ,pp. : 751-755

Spandidos Publications

Access to resources Recommend Favorite